Core Insights - Polyrizon Ltd. has announced significant results from ex vivo studies demonstrating the mucoadhesive strength and extensive nasal surface coverage of its proprietary formulation platform [1][2][3] Group 1: Study Findings - The studies were conducted in collaboration with Prof. Fabio Sonvico's laboratory, using excised rabbit nasal mucosa to simulate human nasal tissues [2] - Advanced ex vivo studies showed that Polyrizon's formulation spreads rapidly and uniformly across the nasal mucosa, forming a consistent surface layer [3] - Mucoadhesion testing indicated that the formulation maintains strong attachment to nasal tissue, even under conditions simulating physiological nasal fluid flow, supporting prolonged efficacy [3][4] Group 2: Product Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a hydrogel-based barrier in the nasal cavity to protect against viruses and allergens [5] - The proprietary Capture and Contain (C&C) hydrogel technology is designed to function as a "biological mask" and is being further developed for enhanced bioadhesion and prolonged retention for drug delivery [5] - An additional technology, Trap and Target (T&T), is in pre-clinical development focused on nasal delivery of active pharmaceutical ingredients [5]
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform